BiBBInstruments AB announces positive news

Yesterday after market close BiBBInstruments AB announced a LOI with TaeWoong Medical USA regarding a distribution agreement covering the U.S. and with a targeted launch of EndoDrill® GI at select U.S. hospitals in autumn 2025, ahead of a nationwide rollout in 2026. TaeWoong Medical Group is active in 79 countries with in excess of 1 million procedures.

At LSIF, we congratulate BiBBInstruments AB on this very encouraging development, which builds on a strong performance also in the previous months with the first commercial order in January, a very successful live-streamed patient case in March with EndoDrill® GI versus Boston Scientific, super data presented at ESGE Days and in April the company reached ongoing clinical evaluation at 10 sites in Europe and the US.

BiBBInstruments AB and CEO Fredrik Lindblad, who has also recently strengthened his management team, is definitely on the right track and at LSIF we are very much looking forward to an exciting H2 2025 and beyond. LSIF is in the Top-10 owners in BiBBInstruments AB.
Link to press release her